Cipla Sets Sights on First-wave Gains from Rollout of Keytruda Biosimilar

What happened

Cipla, through its unit Invagen Pharmaceuticals, partnered with Qilu Pharmaceutical to sell a Keytruda biosimilar in the US. Cipla aims to be among the first wave of launches and expects a significant share of a market worth over $30 billion a year.

Confirmed

Global impact / market context

Cipla's profit per sale on a copied biologic can be large because the original drug earns over $30 billion yearly. An early launch could win shelf space and doctor familiarity before rivals arrive, lifting Cipla's revenue and offsetting research and manufacturing costs.

Analyst inference

Keytruda's patent expires around 2029, so companies are lining up copied versions, which are near-identical biologics made after patent protection ends. Cipla is positioning itself among early entrants, betting that a high single-digit share of this large franchise is still valuable.

Analyst inference

What to watch

1. Keytruda's patent expires around 2029, and Cipla expects to be among the first wave of biosimilar launches, so timing of approval and launch will shape how much of the market it can capture. Confirmed
2. Cipla's management says a high single-digit or near double-digit share of the market is possible, and that share could rise if fewer players compete, which means rival entrants are a key swing factor. Proposed
3. Investors should watch US regulatory approval of QL2107, manufacturing capacity at Qilu, and pricing pressure from other biosimilar makers, since these drive Cipla's revenue, costs and cash available from the launch. Analyst inference

Evidence

• Original source link unavailable